As DMR is an emerging goal in CML and necessary for entry into treatment discontinuation studies [15, 18, 19], RQ-PCR assays with inadequate sensitivity could fail to detect low level BCR-ABL1 fusion transcripts, leading to inappropriate or premature treatment cessation attempts. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.